These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 6411412)

  • 1. Prediction of steady-state concentrations of valproic acid as determined from single plasma concentrations after the first dose.
    May CA; Garnett WR
    Clin Pharm; 1983; 2(2):143-7. PubMed ID: 6411412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-dose model for predicting steady-state valproic acid serum concentrations in seizure patients.
    Pugh CB; Garnett WR; Poynor WJ; Pellock JM
    Clin Pharm; 1984; 3(6):643-9. PubMed ID: 6439455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single dose and steady state pharmacokinetics of valproic acid in adult epileptic patients.
    Miljković B; Pokrajac M; Varagić V; Lević Z
    Int J Clin Pharmacol Res; 1991; 11(3):137-41. PubMed ID: 1809700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steady-state plasma level prediction for haloperidol from a single test dose.
    Javaid JI; Janicak PG; Hedeker D; Sharma RP; Davis JM
    Psychopharmacol Bull; 1991; 27(1):83-8. PubMed ID: 1862210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of three antacids on the bioavailability of valproic acid.
    May CA; Garnett WR; Small RE; Pellock JM
    Clin Pharm; 1982; 1(3):244-7. PubMed ID: 6821035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valproic acid plasma concentration decreases in a dose-independent manner following administration of meropenem: a retrospective study.
    Haroutiunian S; Ratz Y; Rabinovich B; Adam M; Hoffman A
    J Clin Pharmacol; 2009 Nov; 49(11):1363-9. PubMed ID: 19773524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients.
    Ishizaki T; Chiba K; Saito M; Kobayashi K; Iizuka R
    J Clin Psychopharmacol; 1984 Oct; 4(5):254-61. PubMed ID: 6149238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician.
    Dutta S; Reed RC
    J Clin Pharm Ther; 2006 Aug; 31(4):321-9. PubMed ID: 16882100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans.
    Bialer M; Hussein Z; Dubrovsky J; Raz I; Abramsky O
    Isr J Med Sci; 1984 Jan; 20(1):46-9. PubMed ID: 6421770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of food on valproic acid absorption.
    Hamilton RA; Garnett WR; Kline BJ; Pellock JM
    Am J Hosp Pharm; 1981 Oct; 38(10):1490-3. PubMed ID: 6794365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers.
    Slain D; Amsden JR; Khakoo RA; Fisher MA; Lalka D; Hobbs GR
    Pharmacotherapy; 2005 Feb; 25(2):165-70. PubMed ID: 15767232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition of valproic acid in man.
    Gugler R; Schell A; Eichelbaum M; Fröscher W; Schulz HU
    Eur J Clin Pharmacol; 1977 Oct; 12(2):125-32. PubMed ID: 336377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER?
    Reed RC; Dutta S
    Ther Drug Monit; 2006 Jun; 28(3):413-8. PubMed ID: 16778728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualizing phenobarbital dosing in neonates.
    Gilman ME; Toback JW; Gal P; Erkan NV
    Clin Pharm; 1983; 2(3):258-62. PubMed ID: 6883954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Is it preferable to prescribe 1 or 2 daily doses of sodium valproate?].
    Loiseau P; Levy RH; Guyot M; Morselli PL; Brachet-Liermain A
    Nouv Presse Med; 1982 Dec; 11(50):3693-6. PubMed ID: 6820492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications.
    Dutta S; Reed RC; O'Dea RF
    Ann Pharmacother; 2006 Apr; 40(4):619-25. PubMed ID: 16569797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid and blood concentrations of toltrazuril 5% suspension in the horse after oral dosing.
    Furr M; Kennedy T
    Vet Ther; 2000; 1(2):125-32. PubMed ID: 19757559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Problems in serum-level determination during valproic acid therapy].
    Schäfer H; Reith H; Jacobs R; Gabriel KH
    Arzneimittelforschung; 1977; 27(6):1215-21. PubMed ID: 332187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin.
    Rowinsky EK; Jiroutek M; Bonomi P; Johnson D; Baker SD
    Clin Cancer Res; 1999 Apr; 5(4):767-74. PubMed ID: 10213211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.